T1	Intervention 435 532	we performed a randomized, open-label study in which patients were assigned to one of two groups.
T2	Intervention 533 670	Zidovudine was discontinued in group A patients before instituting GM-CSF treatment and was restarted in a graduated fashion over 4 weeks
T3	Intervention 672 774	Group B patients continued on full-dose (1,200 mg/d) zidovudine therapy while beginning GM-CSF therapy
